Free Trial

Embecta (EMBC) Competitors

Embecta logo
$15.01 -0.30 (-1.96%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$15.01 0.00 (0.00%)
As of 09/12/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EMBC vs. LIVN, INSP, WRBY, LQDA, PRCT, LMAT, AORT, EYE, ENOV, and CNMD

Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include LivaNova (LIVN), Inspire Medical Systems (INSP), Warby Parker (WRBY), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry.

Embecta vs. Its Competitors

Embecta (NASDAQ:EMBC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

93.8% of Embecta shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LivaNova had 7 more articles in the media than Embecta. MarketBeat recorded 14 mentions for LivaNova and 7 mentions for Embecta. LivaNova's average media sentiment score of 1.37 beat Embecta's score of 1.14 indicating that LivaNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LivaNova
10 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Embecta has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Embecta has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Embecta$1.12B0.78$78.30M$1.4310.50
LivaNova$1.31B2.34$63.23M-$3.89-14.45

Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Embecta7.58% -23.40% 14.46%
LivaNova -16.13%14.57%6.91%

Embecta presently has a consensus price target of $19.00, indicating a potential upside of 26.58%. LivaNova has a consensus price target of $59.71, indicating a potential upside of 6.22%. Given Embecta's higher possible upside, research analysts clearly believe Embecta is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.75
LivaNova
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Embecta and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EMBC vs. The Competition

MetricEmbectaMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$895.41M$7.66B$5.87B$10.13B
Dividend Yield3.92%2.77%5.68%4.60%
P/E Ratio10.5074.0174.5225.93
Price / Sales0.7842.19517.44183.79
Price / Cash4.5924.1437.5660.44
Price / Book-1.177.3512.166.29
Net Income$78.30M$238.91M$3.28B$270.77M
7 Day Performance0.33%2.63%0.87%3.88%
1 Month Performance7.68%1.47%4.96%4.88%
1 Year Performance-6.30%16.57%60.75%26.01%

Embecta Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EMBC
Embecta
4.5162 of 5 stars
$15.01
-2.0%
$19.00
+26.6%
-4.6%$895.41M$1.12B10.502,100Positive News
LIVN
LivaNova
2.9204 of 5 stars
$56.37
+1.7%
$59.71
+5.9%
+15.3%$3.08B$1.25B-14.492,900Positive News
INSP
Inspire Medical Systems
4.9034 of 5 stars
$93.86
+2.6%
$165.62
+76.4%
-60.6%$2.77B$802.80M54.261,246Positive News
WRBY
Warby Parker
1.6929 of 5 stars
$26.16
-0.3%
$24.06
-8.0%
+86.3%$2.76B$771.32M-373.723,780Positive News
Insider Trade
LQDA
Liquidia Technologies
3.5901 of 5 stars
$27.68
+0.8%
$32.11
+16.0%
+167.4%$2.38B$14M-16.2850Positive News
PRCT
PROCEPT BioRobotics
3.0311 of 5 stars
$40.17
-0.4%
$74.88
+86.4%
-53.8%$2.23B$224.50M-25.92430Positive News
LMAT
LeMaitre Vascular
3.2425 of 5 stars
$95.36
+0.1%
$97.60
+2.3%
+4.7%$2.16B$219.86M46.29490Positive News
AORT
Artivion
2.7279 of 5 stars
$43.87
+0.1%
$40.63
-7.4%
+64.4%$2.07B$388.54M-104.451,600Positive News
EYE
National Vision
2.8018 of 5 stars
$22.94
-2.0%
$24.73
+7.8%
+121.5%$1.82B$1.82B-127.4413,411Positive News
ENOV
Enovis
4.0565 of 5 stars
$30.88
+1.0%
$51.00
+65.1%
-26.5%$1.77B$2.11B-2.177,367News Coverage
Positive News
Insider Trade
Gap Up
CNMD
CONMED
4.1119 of 5 stars
$54.34
+1.1%
$59.80
+10.0%
-31.2%$1.68B$1.31B15.393,900

Related Companies and Tools


This page (NASDAQ:EMBC) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners